[Federal Register: June 3, 2004 (Volume 69, Number 107)]
[Notices]               
[Page 31412]
From the Federal Register Online via GPO Access [wais.access.gpo.gov]
[DOCID:fr03jn04-88]                         

-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

 
Manufacturer of Controlled Substances; Notice of Application

    Pursuant to Sec.  1301.33(a) of Title 21 of the Code of Federal 
Regulations (CFR), this is notice that on April 15, 2004, Cambrex North 
Brunswick, Inc., Technology Centre of New Jersey, 661 Highway One, 
North Brunswick, New Jersey 08902, made application by letter to the 
Drug Enforcement Administration (DEA) for registration as a bulk 
manufacturer of Methadone (9250) and Methadone Intermediate (9254), 
basic classes of controlled substances listed in Schedule II.
    The firm plans to manufacture the controlled substances for 
research and development purposes.
    Any other such applicant and any person who is presently registered 
with DEA to manufacture such substances may file comments or objections 
to the issuance of the proposed registration.
    Any such comments or objections may be addressed, in quintuplicate, 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, United States Department of Justice, 
Washington, DC 20537, Attention: Federal Register Representative, 
Office of Chief Counsel (CCD) and must be filed no later than August 2, 
2004.

    Dated: May 21, 2004.
William J. Walker,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. 04-12465 Filed 6-2-04; 8:45 am]

BILLING CODE 4410-09-M